Cargando…

A small molecule inhibitor MCC950 ameliorates kidney injury in diabetic nephropathy by inhibiting NLRP3 inflammasome activation

BACKGROUND: Diabetic nephropathy (DN) is a lethal diabetic microvascular complication characterized by chronic low-grade inflammation. The NOD-like receptor pyrin domain-containing protein 3 (NLRP3) inflammasome is implicated in the progression of DN. MCC950 is a selective and potent inhibitor of NL...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, CongXiao, Zhu, XinWang, Li, LuLu, Ma, TianKui, Shi, Mai, Yang, Ying, Fan, QiuLing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6684489/ https://www.ncbi.nlm.nih.gov/pubmed/31447572 http://dx.doi.org/10.2147/DMSO.S199802

Ejemplares similares

Inhibiting the NLRP3 Inflammasome Activation with MCC950 Ameliorates Diabetic Encephalopathy in db/db Mice
por: Zhai, Yadong, et al.
Publicado: (2018)

Inhibiting the NLRP3 Inflammasome With MCC950 Ameliorates Isoflurane-Induced Pyroptosis and Cognitive Impairment in Aged Mice
por: Fan, Yunxia, et al.
Publicado: (2018)

The Small Molecule NLRP3 Inflammasome Inhibitor MCC950 Does Not Alter Wound Healing in Obese Mice
por: Lee, James S., et al.
Publicado: (2018)

Targeting the NLRP3 Inflammasome With Inhibitor MCC950 Prevents Aortic Aneurysms and Dissections in Mice
por: Ren, Pingping, et al.
Publicado: (2020)

Adverse renal effects of NLRP3 inflammasome inhibition by MCC950 in an interventional model of diabetic kidney disease
por: Østergaard, Jakob A., et al.
Publicado: (2022)

MCC950, a specific small molecule inhibitor of NLRP3 inflammasome attenuates colonic inflammation in spontaneous colitis mice
por: Perera, Agampodi Promoda, et al.
Publicado: (2018)

Selective NLRP3 Inflammasome Inhibitor MCC950 Suppresses Inflammation and Facilitates Healing in Vascular Materials
por: Grant, Angus J., et al.
Publicado: (2023)

MCC950 closes the active conformation of NLRP3 to an inactive state
por: Tapia-Abellán, Ana, et al.
Publicado: (2019)

A Probe for NLRP3 Inflammasome Inhibitor MCC950 Identifies Carbonic Anhydrase 2 as a Novel Target
por: Kennedy, Cassandra R., et al.
Publicado: (2021)

MCC950 ameliorates ventricular arrhythmia vulnerability induced by heart failure
por: Jiang, Xiaobo, et al.
Publicado: (2022)

NLRP3 inflammasome inhibitor MCC950 can reduce the damage of pancreatic and intestinal barrier function in mice with acute pancreatitis
por: Shen, Yanghui, et al.
Publicado: (2022)

Inhibiting the inflammasome with MCC950 counteracts muscle pyroptosis and improves Duchenne muscular dystrophy
por: Dubuisson, Nicolas, et al.
Publicado: (2022)

MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition
por: Vande Walle, Lieselotte, et al.
Publicado: (2019)

Inhibition of NLRP3 inflammasome by MCC950 improves the metabolic outcome of islet transplantation by suppressing IL-1β and islet cellular death
por: Matsuoka, Taisuke, et al.
Publicado: (2020)

NLRP3 inflammasome inhibitor MCC950 attenuates primary dysmenorrhea in mice via the NF-κB/COX-2/PG pathway
por: Tang, Biao, et al.
Publicado: (2020)

Correction: MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition
por: Walle, Lieselotte Vande, et al.
Publicado: (2019)

Normothermic ex vivo heart perfusion with NLRP3 inflammasome inhibitor Mcc950 treatment improves cardiac function of circulatory death hearts after transplantation
por: Xu, Liwei, et al.
Publicado: (2023)

The selective NLRP3 inhibitor MCC950 hinders atherosclerosis development by attenuating inflammation and pyroptosis in macrophages
por: Zeng, Wenyun, et al.
Publicado: (2021)

MCC950, the NLRP3 Inhibitor, Protects against Cartilage Degradation in a Mouse Model of Osteoarthritis
por: Ni, Bowei, et al.
Publicado: (2021)

MCC950, a Selective Inhibitor of NLRP3 Inflammasome, Reduces the Inflammatory Response and Improves Neurological Outcomes in Mice Model of Spinal Cord Injury
por: Jiao, Jianhang, et al.
Publicado: (2020)

Inhibiting the NLRP3 inflammasome with MCC950 ameliorates retinal neovascularization and leakage by reversing the IL-1β/IL-18 activation pattern in an oxygen-induced ischemic retinopathy mouse model
por: Sui, Ailing, et al.
Publicado: (2020)

The Selective NLRP3-inflammasome inhibitor MCC950 Mitigates Post-resuscitation Myocardial Dysfunction and Improves Survival in a Rat Model of Cardiac Arrest and Resuscitation
por: Zheng, Guanghui, et al.
Publicado: (2022)

MCC950 Ameliorates Acute Liver Injury Through Modulating Macrophage Polarization and Myeloid-Derived Suppressor Cells Function
por: Yan, Wei, et al.
Publicado: (2021)

Inhibiting MicroRNA-503 and MicroRNA-181d with Losartan Ameliorates Diabetic Nephropathy in KKAy Mice
por: Zhu, XinWang, et al.
Publicado: (2016)

MCC950, a selective NLPR3 inflammasome inhibitor, improves neurologic function and survival after cardiac arrest and resuscitation
por: Jiang, Maorong, et al.
Publicado: (2020)

Curcumin Ameliorates Diabetic Nephropathy by Suppressing NLRP3 Inflammasome Signaling
por: Lu, Miaomiao, et al.
Publicado: (2017)

Intraperitoneal Injection of MCC950 Inhibits the Progression of Myopia in Form-Deprivation Myopic Mice
por: Chen, Zhengyu, et al.
Publicado: (2023)

Blockage of KHSRP-NLRP3 by MCC950 Can Reverse the Effect of Manganese-Induced Neuroinflammation in N2a Cells and Rat Brain
por: Singh, Sharad, et al.
Publicado: (2022)

Protection of Mcc950 against high-glucose-induced human retinal endothelial cell dysfunction
por: Zhang, Yi, et al.
Publicado: (2017)

MCC950, a Selective NLRP3 Inhibitor, Attenuates Adverse Cardiac Remodeling Following Heart Failure Through Improving the Cardiometabolic Dysfunction in Obese Mice
por: Wang, Menglong, et al.
Publicado: (2022)

The Role of NLRP3 Inflammasome in IgA Nephropathy
por: Wu, Xiaofang, et al.
Publicado: (2022)

LincRNA-Gm4419 knockdown ameliorates NF-κB/NLRP3 inflammasome-mediated inflammation in diabetic nephropathy
por: Yi, Hong, et al.
Publicado: (2017)

Interleukin-22 ameliorated renal injury and fibrosis in diabetic nephropathy through inhibition of NLRP3 inflammasome activation
por: Wang, Shaofei, et al.
Publicado: (2017)

Astragaloside IV ameliorates diabetic nephropathy in db/db mice by inhibiting NLRP3 inflammasome-mediated inflammation
por: Feng, Hui, et al.
Publicado: (2021)

Targeting of NLRP3 inflammasome with gene editing for the amelioration of inflammatory diseases
por: Xu, Congfei, et al.
Publicado: (2018)

MCC Regulator of WNT Signaling Pathway (MCC) Is a Podocyte Essential Gene
por: Song, Hui, et al.
Publicado: (2021)

DsbA-L Ameliorates Renal Injury Through the AMPK/NLRP3 Inflammasome Signaling Pathway in Diabetic Nephropathy
por: Yang, Ming, et al.
Publicado: (2021)

Combined Therapy With Polyethylene Glycol‐20k and MCC950 Preserves Post‐Resuscitated Myocardial Function in a Rat Model of Cardiac Arrest and Cardiopulmonary Resuscitation
por: Liang, Lian, et al.
Publicado: (2021)

Inhibition of the NLRP3 Inflammasome Activation by Manoalide Ameliorates Experimental Autoimmune Encephalomyelitis Pathogenesis
por: Li, Cong, et al.
Publicado: (2022)

The Role of the NLRP3 Inflammasome in Mediating Glomerular and Tubular Injury in Diabetic Nephropathy
por: Williams, B. M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p21q5dfmh9re3nsgpb3sbh5ld4